BRIEF—Provention Bio appoints Jason Hoitt as chief commercial officer

Provention Bio has appointed Jason Hoitt as chief commercial officer. Mr Hoitt was formerly CCO at Dova Pharmaceuticals, which was taken over last year by Swedish Orphan Biovitrum.

Taking on development and execution of the firm’s global commercial strategy for PRV-031 (teplizumab), he said Provention was “preparing to launch its Breakthrough Therapy Designation lead program with the potential to disrupt and transform the T1D landscape.”

Chief executive Ashleigh Palmer said the firm would “begin to build our commercial capabilities,” while continuing to “evaluate potential partnerships for all indications and geographies.”